Christine Mikail Cvijic Sells 4,045 Shares of Neurogene (NASDAQ:NGNE) Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 4,045 shares of the company’s stock in a transaction on Friday, March 13th. The stock was sold at an average price of $20.81, for a total transaction of $84,176.45. Following the transaction, the chief financial officer owned 105,798 shares of the company’s stock, valued at $2,201,656.38. This represents a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Neurogene Stock Down 7.5%

Shares of NASDAQ NGNE opened at $19.50 on Thursday. The company’s 50-day simple moving average is $19.18 and its 200-day simple moving average is $21.63. Neurogene Inc. has a 52-week low of $6.88 and a 52-week high of $37.27. The firm has a market cap of $302.06 million, a price-to-earnings ratio of -4.74 and a beta of 1.53.

Wall Street Analysts Forecast Growth

NGNE has been the subject of several research reports. Canaccord Genuity Group initiated coverage on Neurogene in a research note on Friday, February 27th. They set a “buy” rating for the company. Wall Street Zen downgraded Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a research note on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $70.00 price target on shares of Neurogene in a research report on Tuesday, January 13th. Finally, Lifesci Capital initiated coverage on Neurogene in a research note on Monday, January 26th. They issued an “outperform” rating and a $50.00 price objective for the company. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of NGNE. BNP Paribas Financial Markets boosted its holdings in shares of Neurogene by 89.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after purchasing an additional 978 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Neurogene by 43.6% in the second quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock valued at $61,000 after purchasing an additional 1,232 shares during the last quarter. Daiwa Securities Group Inc. acquired a new stake in shares of Neurogene in the fourth quarter valued at approximately $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after buying an additional 1,059 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Neurogene during the fourth quarter worth $165,000. 52.37% of the stock is owned by hedge funds and other institutional investors.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.